Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

Thursday, July 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health, a precision oncology company, will report its second quarter 2026 financial results on July 30, 2026. The announcement includes a conference call scheduled for 1:30 p.m. PT, which will be webcasted for investor access. This event highlights the company's commitment to transparency and investor relations.
Price reaction · baseline $164.08 (2026-07-09 close) · hit after-hours · clean, no other GH news in the window
day 0 close · peak
-2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Guardant Health is actively engaging with investors.
  • The company is expected to share important financial results.
  • The webcast allows for broader accessibility to financial information.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will

Frequently Asked Questions

When will Guardant Health report its Q2 2026 results?

Guardant Health will report its Q2 2026 financial results on July 30, 2026.

What time is the Guardant Health conference call?

The conference call will begin at 1:30 p.m. Pacific Time.

Where can I access the webcast for the results?

The webcast will be available on the 'Investors' section of Guardant Health's website.

What is the significance of this financial report?

The report will provide insights into Guardant Health's performance and future outlook.

ShareAdd on Google
Tags: GH Viatris Investor Conferences Healthcare Guardant Health financial results Q2 2026 webcast investors
Last updated: Jul 9, 2026

Biotech snapshot

Cash runway
$1103M liquidity · $22M/mo burn
~48 mo
Minimal dilution risk